Menu
Search
Home > Courses > Best of ACTHIV 2020: HIV the Basics - HIV Pathogenesis

Best of ACTHIV 2020: HIV the Basics - HIV Pathogenesis

Best of ACTHIV 2020: HIV the Basics - HIV Pathogenesis
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Release Date: 8/20/2020
Termination Date: 12/31/2021
Review Date: 12/31/2020
Presenter
  • Eric S. Daar, MD
    Harbor-UCLA Medical Center Professor of Medicine
    David Geffen School of Medicine at UCLA
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Describe the current understanding of HIV pathogenesis and the natural history of infection
  2. Explain the relationship between pathogenesis and HIV treatment decisions
  3. Review the latest research on HIV cure strategies
Presenter Bio
Eric Daar, MD
Eric Daar, MD is the Chief of the Division of HIV Medicine at Harbor-UCLA Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. He is an Infectious Diseases-trained clinician-investigator with more than 25 years of experience providing HIV care and conducting clinical and translational research related to HIV/AIDS. His research focus has been on the development and implementation of studies to address HIV pathogenesis and clinical questions related to optimal management of HIV infection. He has received research support from NIH, the State of California and Industry, including currently being the site Principal Investigator on multiple NIH-funded projects including the AIDS Clinical Trials Group (ACTG). He is also a member of the Health and Human Services Panel for Adult and Adolescent HIV Treatment Guidelines. His research has resulted in him being author on more than 500 peer-reviewed manuscripts and abstracts.
Continuing Education Credit

The enduring material is jointly provided by Beaumont Health, American Academy of CME, Inc., and ACTHIV Institute.

The 14th Annual American Conference for the Treatment of HIV (ACTHIV) was held virtually August 20-22, 2020. The Conference was supported by the Clinical Education Initiative, New York State Department of Health, AIDS Institute. The conference and this Best of ACTHIV web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV HealthCare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course evaluation.

FACULTY:

Eric S. Daar, MD, Harbor-UCLA Medical Center, Professor of Medicine, David Geffen School of Medicine at UCLA.

Estimated time to complete: 30 minutes

TARGET AUDIENCE

Members of the HIV care team who are frontline providers of care to persons at risk for or are living with HIV infection, including physicians (both specialists and primary care/family medicine), nurse practitioners, physician assistants, nurses, pharmacists, case managers and other care team members are also encouraged to participate.

Learning Objectives

As a result of participating in this activity, participants should be better able to:

  • Describe the current understanding of HIV pathogenesis and the natural history of infection
  • Explain the relationship between pathogenesis and HIV treatment decisions
  • Review the latest research on HIV cure strategies

CREDIT

ACTHIV CME

In support of improving patient care, this activity has been planned and implemented by Beaumont Health, American Academy of CME, Inc., and the ACTHIV Institute. Beaumont Health is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:

Beaumont Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACTHIV CME

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., Beaumont Health, and the ACTHIV Institute. Beaumont Health is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses Practitioners and Nurses: 

American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.2 pharmacotherapeutic contact hours).

Physician Assistants:

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until December 31, 2021. PAs should only claim credit commensurate with the extent of their participation.

All other members of the HIV Care team will receive a certificate of participation.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT 

In order to obtain your certificate of credit, you must read the CME/CE information, review the full content of the activity, and complete the online evaluation.

Upon submission of the evaluation, your certificate for the activity will be made available immediately to print online.

DISCLOSURES

According to the disclosure policy of the Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity. 

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, or ACTHIV Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity does not contain off-label discussion.

Faculty Disclosure

Eric S. Daar, MD: discloses the following relevant financial relationships with commercial interests: Consultant: Gilead Sciences, ViiV Healthcare; Grant/Research Support: Gilead Sciences, Merck & Co., ViiV Healthcare.

Planner Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose: Julie Barroso, PhD, ANP, FAAN; John Brooks, MD; Sherrillyn Crooks, PA-C; Carlos del Rio, MD; Courtney V Fletcher, PharmD; John JD Juchniewicz, MCIS, CHCP; Bill G Kapogiannis, MD; Deborah Kim, RPh; H. Nina Kim, MD, MSc; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Lorenzo McFarland, DHA, MPH, MSW, PMP; Edward Moylan, RP; Paul Miniter, MS; Asa Radix, MD, MPH; Dianne Rausch, PhD; Renslow Sherer, MD; Cheryl Smith, MD; Brooke Taylor, MPH, CHCP; Andrea Weddle, MSW; Susan Weiss, FNP-BC, MSN, AAHIVS; Barbara A. Young, MSW, LCSE, LCADC, SAC

The following individuals have relevant financial relationships with commercial interests to disclose:

Oluwatoyin Adeyemi, MD: Advisory Board: Gilead Sciences; Grant/Research Support: Gilead Sciences 
Roger Bedimo, MD: Advisory Board: Merck & Co. & Co., ViiV Healthcare; Grant/Research Support: ViiV Healthcare
Michelle Cespedes, MD, MS: Advisory Board: Gilead Sciences, ViiV Healthcare 
Eric Daar, MD: Advisory Board: Gilead Sciences, ViiV Healthcare; Grant/Research Support: Gilead Sciences, Merck & Co., ViiV Healthcare 
Donna Futterman, MD: Grant/Research Support: Gilead Sciences 
Rajesh Gandhi, MD: Advisory Board: Merck & Co. 
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board: ViiV Healthcare; Grant/Research Support: ViiV Healthcare; Speaker's Bureau: Gilead Sciences, ViiV Healthcare 
Tonia Poteat, PhD, PA-C: Advisory Board: Gilead Sciences; Grant/Research Support: Gilead Sciences, ViiV Healthcare  
Jennifer C. Price, MD, PhD: Advisory Board: Surrozen, Theratechnologies; Shareholder (Spouse/Partner): Abbvie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson; Grant/Research Support: Gilead Sciences, Merck & Co. 
Jason Schafer, PharmD, MPH: Advisory Board: Merck & Co.; Grant/Research Support: Merck & Co., Gilead Sciences 
William Short, MD, MPH: Advisory Board: ViiV Healthcare 
Babafemi Taiwo, MBBS: Advisory Board: ViiV Healthcare, Gilead Sciences, Merck & Co. 
Pablo Tebas, MD: Advisory Board: Merck & Co., ViiV Healthcare, Gilead Sciences; Grant/Research Support: Merck & Co., ViiV Healthcare, Gilead Sciences, Inovio, Genone
Melanie Thompson, MD: Grant/Research Support: Bristol-Myers Squibb, Cytodyn, Cepheid, Gilead Sciences, GlaxoSmithKline, Merck & Co., ViiV Healthcare 

Privacy Policy

For more information about Beaumont’s privacy policy, please access https://www.beaumont.org/patients-families/patients-rights-privacy/privacy

For more information about the Academy’s privacy policy, please access http://www.academycme.org/privacy.htm

For questions related to physician credit, contact: cme@beaumont.edu  

For questions related to nursing (including NPs) and PA credit, contact CEservices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later 
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2020 American Academy of CME, Inc., Beaumont Health, and ACTHIV Institute.

Resources:

  • Deeks SG, et al. HIV infection. Nature Reviews Disease Primers. 2015. Available at: https://www.nature.com/articles/nrdp201535
  • Perelson AS, et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Science 1996;271:1582-1586.  
  • Benchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine. 2006;12:1365-1371.
  • Siliciano JE, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med 2003; 9(6):727-728. 
  • Eden A, et al. HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. JID. 2010;202:1819-1825.
  • Halfon P, et al. Semen May Harbor HIV Despite Effective HAART: Another Piece in the Puzzle. PLoS ONE; 2010; 5(5):e10569.